Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
9.37
+0.01 (0.11%)
At close: Nov 9, 2026, 4:00 PM EST
9.37
0.00 (0.00%)
After-hours: Nov 9, 2026, 8:00 PM EST
Pelthos Therapeutics Revenue
Pelthos Therapeutics had revenue of $15.60M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $43.30M. In the year 2025, Pelthos Therapeutics had annual revenue of $16.80M. That makes Pelthos Therapeutics the 29,005th largest company in the world by revenue and 3,878th in the United States.
Revenue (ttm)
$43.30M
Revenue Growth
n/a
P/S Ratio
0.85
Revenue / Employee
$470,696
Employees
92
Market Cap
35.87M
Revenue by Segment
- Commercial Operations 16.21M 96.5%
- Research and Development Operations 589.00K 3.5%
Fiscal year ended Dec 31, 2025 See the full Pelthos Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.80M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Hyperion DeFi | 1.40M |
| Serina Therapeutics | 130.00K |
| INmune Bio | 50.00K |
| Impact BioMedical | 35.00K |
PTHS News
- 5 days ago - Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026 - GlobeNewsWire
- 10 days ago - Pelthos Therapeutics Inc trading resumes - TheFly
- 10 days ago - Pelthos Therapeutics Inc trading halted, volatility trading pause - TheFly
- 10 days ago - Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin - GlobeNewsWire
- 13 days ago - Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution - GlobeNewsWire
- 14 days ago - Pelthos Therapeutics price target lowered to $30 from $45 at Alliance Global - TheFly
- 4 weeks ago - Pelthos Therapeutics price target lowered to $40 from $50 at Lake Street - TheFly
- 4 weeks ago - Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewsWire